Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repair of Sinus Venosus Atrial Septal Defect in 2 Patients With Severe Pulmonary Arterial Hypertension.

Pulmonary circulation·2026
Same author

Economic reform can save antibiotic innovation.

Nature·2026
Same author

A Call to Reform Congenital Interventional Cardiology Training: A PICES Community Survey.

Pediatric cardiology·2026
Same author

Spike on a bike: mobile harm reduction in action.

Harm reduction journal·2026
Same author

Transcatheter Pulmonary Valve Implantation With the Alterra Adaptive Prestent and SAPIEN 3 Transcatheter Heart Valve: 3-Year Pooled Outcomes of the ALTERRA Trials.

Circulation. Cardiovascular interventions·2026
Same author

Optical Coherence Tomography in Pediatric Airway Surgery: A Case Series and Focused Review.

The Laryngoscope·2026

Related Experiment Video

Updated: May 29, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Aspirin bleeding in perspective.

Gareth Morgan1, Peter Elwood

  • 1Department of Primary Care and Public Health, Cardiff University, University Hospital of Wales, Wales, UK. morgan@fforrdbeck.fsnet.co.uk

Quality in Primary Care
|September 10, 2011
PubMed
Summary

Aspirin is recommended after vascular events, but its use for primary prevention is unclear. Side effects like heartburn may deter more people than bleeding risks.

Area of Science:

  • Cardiology
  • Gastroenterology
  • Oncology

Background:

  • Aspirin is a standard adjunct therapy for secondary prevention of vascular events.
  • The role of aspirin in primary prevention of vascular events requires further clarification.
  • Emerging evidence suggests aspirin may reduce the risk of colorectal cancer.

Purpose of the Study:

  • To evaluate the benefit-versus-risk balance of aspirin therapy.
  • To assess the influence of aspirin's potential bowel cancer risk reduction on its overall utility.
  • To understand the impact of aspirin's side effects on patient adherence.

Main Methods:

  • Review of existing clinical trial data and epidemiological studies.
  • Analysis of the risk of vascular events versus the risk of bleeding and gastrointestinal side effects.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Experiment Videos

Last Updated: May 29, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

  • Assessment of aspirin's effect on colorectal cancer incidence.

    • Main Results:

    • Aspirin therapy is clearly beneficial for secondary prevention of vascular events.
    • The benefit-risk profile for primary prevention is less defined and may vary by individual risk factors.
    • Gastrointestinal symptoms, such as heartburn, affect approximately 10% of aspirin users and may significantly impact quality of life.
    • The risk of experiencing bothersome side effects might outweigh the perceived bleeding risk for some individuals.

    Conclusions:

    • While aspirin is crucial for secondary vascular event prevention, its primary prevention role needs careful consideration.
    • The potential benefit of reducing bowel cancer risk may influence the decision-making process for aspirin use.
    • Patient-reported symptoms and quality of life are critical factors in the benefit-risk assessment of long-term aspirin therapy, potentially impacting adherence more than bleeding concerns.